Literature DB >> 24012397

Targeting the p53 pathway.

Vita M Golubovskaya1, William G Cance.   

Abstract

This article summarizes data on translational studies to target the p53 pathway in cancer. It describes the functions of the p53 and Mdm-2 signaling pathways, and discusses current therapeutic approaches to target p53 pathways, including reactivation of p53. In addition, direct interaction and colocalization of the p53 and focal adhesion kinase proteins in cancer cells have been demonstrated, and different approaches to target this interaction are reviewed. This is a broad review of p53 function as it relates to the diagnosis and treatment of a wide range of cancers.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; FAK; Mdm-2; Survival; p53

Mesh:

Substances:

Year:  2013        PMID: 24012397      PMCID: PMC3810242          DOI: 10.1016/j.soc.2013.06.003

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  120 in total

1.  Pharmacological rescue of mutant p53 conformation and function.

Authors:  B A Foster; H A Coffey; M J Morin; F Rastinejad
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

2.  The tumour suppressor protein p53 can repress transcription of cyclin B.

Authors:  K Krause; M Wasner; W Reinhard; U Haugwitz; C L Dohna; J Mössner; K Engeland
Journal:  Nucleic Acids Res       Date:  2000-11-15       Impact factor: 16.971

3.  Nuclear localization and apoptotic regulation of an amino-terminal domain focal adhesion kinase fragment in endothelial cells.

Authors:  M Lobo; I Zachary
Journal:  Biochem Biophys Res Commun       Date:  2000-10-05       Impact factor: 3.575

4.  Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine.

Authors:  E Sugikawa; T Hosoi; N Yazaki; M Gamanuma; N Nakanishi; M Ohashi
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

5.  Negative regulation of bcl-2 expression by p53 in hematopoietic cells.

Authors:  Y Wu ; J W Mehew; C A Heckman; M Arcinas; L M Boxer
Journal:  Oncogene       Date:  2001-01-11       Impact factor: 9.867

6.  Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes.

Authors:  W G Cance; J E Harris; M V Iacocca; E Roche; X Yang; J Chang; S Simkins; L Xu
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

7.  p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest.

Authors:  J I Johnsen; O N Aurelio; Z Kwaja; G E Jörgensen; N S Pellegata; R Plattner; E J Stanbridge; J F Cajot
Journal:  Int J Cancer       Date:  2000-12-01       Impact factor: 7.396

8.  Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex.

Authors:  M J May; F D'Acquisto; L A Madge; J Glöckner; J S Pober; S Ghosh
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

9.  CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.

Authors:  Xiuwei Tang; Yucui Zhu; Lydia Han; Arianna L Kim; Levy Kopelovich; David R Bickers; Mohammad Athar
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice.

Authors:  Chinthalapally V Rao; Malisetty V Swamy; Jagan M R Patlolla; Levy Kopelovich
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

View more
  9 in total

1.  TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer.

Authors:  Ana Coelho; Augusto Nogueira; Sílvia Soares; Joana Assis; Deolinda Pereira; Isabel Bravo; Raquel Catarino; Rui Medeiros
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

2.  14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2.

Authors:  Jia Xu; Sunil Acharya; Ozgur Sahin; Qingling Zhang; Yohei Saito; Jun Yao; Hai Wang; Ping Li; Lin Zhang; Frank J Lowery; Wen-Ling Kuo; Yi Xiao; Joe Ensor; Aysegul A Sahin; Xiang H-F Zhang; Mien-Chie Hung; Jitao David Zhang; Dihua Yu
Journal:  Cancer Cell       Date:  2015-02-09       Impact factor: 31.743

Review 3.  Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy.

Authors:  Le Zhang; Ningning Hou; Bing Chen; Chengxia Kan; Fang Han; Jingwen Zhang; Xiaodong Sun
Journal:  Front Pharmacol       Date:  2022-05-24       Impact factor: 5.988

Review 4.  Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.

Authors:  Young Kwang Chae; Su Yun Chung; Andrew A Davis; Benedito A Carneiro; Sunandana Chandra; Jason Kaplan; Aparna Kalyan; Francis J Giles
Journal:  Oncotarget       Date:  2015-11-10

5.  Etoposide induces cell death via mitochondrial-dependent actions of p53.

Authors:  Sarwat Jamil; Irene Lam; Maryam Majd; Shu-Huei Tsai; Vincent Duronio
Journal:  Cancer Cell Int       Date:  2015-08-07       Impact factor: 5.722

6.  Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia.

Authors:  Wei Ju; Meili Zhang; Michael Petrus; Michiyuki Maeda; Cynthia A Pise-Masison; Thomas A Waldmann
Journal:  Retrovirology       Date:  2014-06-02       Impact factor: 4.602

7.  Compound A398, a novel podophyllotoxin analogue: cytotoxicity and induction of apoptosis in human leukemia cells.

Authors:  Alethéia L Silveira; Glaúcia V Faheina-Martins; Raquel C Maia; Demetrius A M Araújo
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

Review 8.  Chemical Variations on the p53 Reactivation Theme.

Authors:  Carlos J A Ribeiro; Cecília M P Rodrigues; Rui Moreira; Maria M M Santos
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-13

Review 9.  Sex differences in cancer mechanisms.

Authors:  Joshua B Rubin; Joseph S Lagas; Lauren Broestl; Jasmin Sponagel; Nathan Rockwell; Gina Rhee; Sarah F Rosen; Si Chen; Robyn S Klein; Princess Imoukhuede; Jingqin Luo
Journal:  Biol Sex Differ       Date:  2020-04-15       Impact factor: 5.027

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.